Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kazuhiro Soshiroda"'
Autor:
Yutaro Ohno, Eri Okita, Mika Kawai-Uchida, Youji Shoukei, Kazuhiro Soshiroda, Tomoyuki Kanda, Shinichi Uchida
Publikováno v:
Journal of Pharmacological Sciences, Vol 152, Iss 3, Pp 193-199 (2023)
The adenosine A2A receptor antagonist/inverse agonist, KW-6356 has been shown to be effective in Parkinson's disease (PD) patients as monotherapy and as an adjunct therapy to L-3,4-dihydroxyphenylalanine (L-DOPA)/decarboxylase inhibitor. However, the
Externí odkaz:
https://doaj.org/article/c813e07e2733429a92c3bfbdfcba0ff4
Autor:
Yutaro Ohno, Eri Okita, Mika Kawai-Uchida, Naoko Fukuda, Youji Shoukei, Kazuhiro Soshiroda, Koji Yamada, Tomoyuki Kanda, Shinichi Uchida
Publikováno v:
European Journal of Pharmacology. 950:175773
Autor:
Tomoyuki Kanda, Eri Okita, Shin-ichi Uchida, Akihisa Mori, Mika Kawai-Uchida, Kazuhiro Soshiroda, Peter Jenner
Publikováno v:
European Journal of Pharmacology. 766:25-30
The adenosine A2A receptor antagonist, istradefylline improves motor function in patients with advanced Parkinson's disease (PD) optimally treated with a combination of L-DOPA and a dopamine agonist without increasing the risk of troublesome dyskines
Autor:
Shin Ichi Uchida, Eri Okita, Kazuhiro Soshiroda, Akihisa Mori, Mika Kawai-Uchida, Tomoyuki Kanda, Peter Jenner
Publikováno v:
European Journal of Pharmacology. 747:160-165
The adenosine A2A receptor antagonist, istradefylline, enhances anti-parkinsonian activity in patients with advanced Parkinson׳s disease (PD) already treated with combinations of L-DOPA and dopamine agonist drugs but who are still exhibiting prolong